NL-OMON34925已完成2 期
A Randomized, Double - Masked, Placebo - Controlled Study of PRM - 151 in the Prevention of Postoperative Scarring in Glaucoma Patients Following Primary Trabeculectomy. - PRM-151 Trabulectomy Scarring prevention V1
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion Criteria
- •1. Men or women of nonchildbearing potential (WONCBP) aged 18 years and older at screening.
- •WONCBP may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for >=1 year (with follicle stimulating hormone [FSH] >=38 mIU/mL) and must have a negative pregnancy test result at screening. Women who are surgically sterile must provide documentation of the procedure by an operative report or by ultrasound. Sexually active men must agree to use a medically acceptable form of contraception from day 1 to 12 weeks after the last dose of test article.
- •2. Diagnosis of chronic angle-closure glaucoma or open-angle glaucoma, phakic or pseudophakic, with visual field or optic disc changes characteristic of glaucoma. For pseudophakic glaucoma patients, the cataract surgery performed was with phacoemulsification and through a corneal incision.
- •3. Suitable candidate for trabeculectomy in the study eye which the physician deems as medically necessary.
排除标准
- •Exclusion Criteria
- •Medical History
- •1. Diagnosis of glaucoma other than chronic angle-closure glaucoma or open-angle glaucoma (ie., uveitic, traumatic or neovascular glaucoma).
- •2. Any previous ocular surgeries in the study eye involving the upper conjunctiva and sclera.
- •3. History of laser surgeries in the study eye within 90 days before day 1.
- •4. Presence or history of any disease that could affect wound healing.
- •5. Any asymmetric abnormality of the anterior segment which requires additional intervention (surgery or medication).
- •6. Any abnormality other than glaucoma in the study eye that could affect tonometry.
- •7. Presence or history of uveitis within 10 years or any other ocular infection or inflammation within 14 days before day 1.
- •8. Presence or history of any abnormality or disorder that could interfere with the study procedure or prevent the successful completion of the study.
- •9. Clear corneal phacoemulsification performed within 90 days before day 1.
- •10. Any significant unstable cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
- •11. Any surgical or medical condition that may interfere with the absorption, distribution, metabolism, or excretion of the test article or the assessment of the effect of the test article.
- •12. History of drug abuse or alcohol abuse within 1 year before screening that may interfere with the subject*s ability to comply with the protocol requirements.
- •Physical and Laboratory Findings
- •13. Conjunctival scarring precluding a trabeculectomy.
- •14. Vitreous in the anterior chamber.
- •15. Proliferative retinopathy.
- •16. Abnormality preventing reliable applanation tonometry in each eye.
- •Allergies and Adverse Drug Reactions
- •17. History of drug anaphylaxis to any of the test articles used in this study.
- •Prohibited Treatments
- •18. Hemodialysis.
- •19. Use of any anti-scarring ophthalmologic agents within 90 days before day 1.
- •20. Use of antimetabolites or systemic steroids within 90 days before day 1.
- •21. Treatment with cancer chemotherapy within 30 days before day 1.
- •22. Use of any investigational drug within 30 days before day 1.
研究者
相似试验
进行中（未招募）
不适用
A placebo controlled trial investigating the safety and effectiveness of AZD4017 in patients with raised intra-ocular pressureRaised Intra-Ocular Pressure or primaryopen angle glaucoma (POAG) on anti-glaucoma monotherapy that has been stable indose for at least 30 days prior to screening.MedDRA version: 14.1Level: LLTClassification code 10036719Term: Primary open angle glaucomaSystem Organ Class: 10015919 - Eye disordersMedDRA version: 14.1Level: LLTClassification code 10022809Term: Intraocular pressure raisedSystem Organ Class: 10022891 - InvestigationsEUCTR2010-020932-20-SEAstraZeneca AB60
进行中（未招募）
1 期
A placebo controlled trial investigating the safety and effectiveness of AZD4017 in patients with raised intra-ocular pressureEUCTR2010-020932-20-GBAstraZeneca AB60
进行中（未招募）
不适用
Efficacy and safety of gevokizumab in the treatment of patients with active non-infectious uveitis currently controlled with systemic treatmentEUCTR2012-001609-25-ITXOMA300
进行中（未招募）
不适用
A randomized, double-masked, placebo-controlled two cross-over study comparing the effects of moxaverine and placebo on ocular blood flowhealthy personsEUCTR2006-001783-23-ATRSAPHARM Arzneimittel GmbH & Co. KG16
已完成
3 期
A Clinical trial to study the effect of no treatment and polyhexamethylene biguanide in the outcome of keratoconjunctivitis caused by microsporidia.CTRI/2009/091/000792il90